Medical Technology

News

• • Corporate

  Cicor wins an important contract from a leading European A&D equipment provider

  Media Release

  08/18/2025

  Bronschhofen, 18 August 2025 – The Cicor Group (SIX Swiss Exchange: CICN) has secured an important purchase order from a top-five European provider of aerospace and defence (A&D) equipment. The advanced substrates will be used for airborne radar systems and manufactured at the Wangs (Switzerland) site.

  Read more

  Read more
• • Corporate

  Cicor completes acquisition of MADES, strengthens A&D market leadership and sees no material impact from US tariffs

  Media Release

  08/04/2025

  Bronschhofen, 4 August 2025 – The Cicor Group (SIX Swiss Exchange: CICN) today announces the closing of the acquisition of 100% of the shares in Spanish electronics company MADES S.A.U., headquartered in Málaga (Spain), from the French Latecoere Group. With this acquisition, Cicor strengthens its position as the leading pan-European provider of electronics design and manufacturing services (EMS) for the rapidly growing European aerospace and defence (A&D) market. The expansion into Spain unlocks new customer potential across this sector and underlines Cicor’s role as the partner of choice for mission-critical applications.

  Read more

  Read more
• • Ad hoc 2025

  Cicor grows double-digit again and creates strong foundation for further expansion

  Ad hoc announcement pursuant to Art. 53 LR

  07/23/2025

  Bronschhofen, 23 July 2025 - In the first half of 2025, Cicor Group (SIX Swiss Exchange: CICN) took a significant step towards its ambition of becoming the pan-European leader in its chosen markets as announced in the strategy 2028, expanding market presence into France and Spain. Net sales reached CHF 280.7 million, an increase of 21.4% to the previous year (CHF 231.3 million). With increased momentum in the second quarter, Cicor achieved a positive book-to-bill rate of 1.02 in the reporting period, compared to 0.87 in H1 2024. Underlying profitability developed positively with an EBITDA margin of 11.2% (H1 2024: 10.7%) when excluding the effects from the Éolane France integration. Cicor generated a strong underlying Free Cash Flow of CHF 18.5 million – excluding acquisitions and before integration of Éolane France.

  Read more

  Read more
• Load more